Study of MPDL3280A (ANTI PD-L1 ANTIBODY) in Patients with PD-L1-selected, High-risk Muscle-invasive Bladder Cancer after Surgery

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005603-25

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of adjuvant MPDL3280A treatment in patients with programmed death ligand 1 (PD L1) selected muscle invasive bladder cancer (MIBC), as measured by disease-free survival (DFS)


Critère d'inclusion

  • Muscle-invasive bladder cancer